Addressing the ‘hypoxia paradox’ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues

Addressing the ‘hypoxia paradox’ in severe COVID-19: literature review and report of four cases treated with erythropoietin analogues

Abstract Background Since fall 2019, SARS-CoV-2 spread world-wide, causing a major pandemic with estimated ~ 220 million subjects affected as of September 2021. Severe COVID-19 is associated with multiple organ failure, particularly of lung and kidney, but also grave neuropsychiatric manifestations....

Full description

Bibliographic Details
Main Authors: Martin Begemann, Oliver Gross, Dominik Wincewicz, Rüdiger Hardeland, Vinicius Daguano Gastaldi, Eduard Vieta, Karin Weissenborn, Kamilla W. Miskowiak, Onnen Moerer, Hannelore Ehrenreich
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Molecular Medicine
Subjects:
Recombinant human EPO
Darbepoetin
Neuroprotection
Treatment
Signaling
Critical care
Online Access:https://doi.org/10.1186/s10020-021-00381-5

Internet

https://doi.org/10.1186/s10020-021-00381-5

Similar Items